| Autor: |
Capoluongo, Ettore D., Amato, Felice, Castaldo, Giuseppe |
| Předmět: |
|
| Zdroj: |
Clinical Chemistry & Laboratory Medicine; Jul2020, Vol. 58 Issue 7, p1162-1164, 3p |
| Abstrakt: |
Keywords: Chloroquine; COVID-19; G6PD EN Chloroquine COVID-19 G6PD 1162 1164 3 06/15/20 20200701 NES 200701 To the Editor, I In vitro i data suggest that chloroquine (the most used antimalarial drug) inhibits SARS CoV-2 replication as many previous papers have shown as this molecule displays an I in vitro i activity against various viruses (e.g. chikungunya virus), although without any reliable benefit in animal models [[1]]. Administering hydroxychloroquine or other chloroquine salts to elderly patients with I G6PD i deficiency represents a higher risk to generate adverse effects due to these medications. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
